CSF3 and non-Hodgkin lymphoma: A Phase II Study of Plerixafor, Combined with G-CSF for CD34(+) Cell Mobilization in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Autologous Transplantation.